Iron Replacement in Oesophagogastric Neoplasia
NCT01927328
Interventional
Phase 4
Unknown status
IRON
40 eligible patients with confirmed esophageal or gastric adenocarcinoma and anemia will be randomized to a control or intervention group for management of this anemia. The control group treatment will consist of standard treatments as governed by the clinical team (eg oral iron, blood transfusions) whilst the intervention group will be treated with intravenous iron III isomaltoside (Monofer ®). It is hypothesized that intravenous iron supplementation is more efficacious than standard therapies.
Aug 31,2013
All
18 Years
N/A
18 Years
N/A
40